Uterine cavity vegetations
Conditions
Interventions
A (cyclopofol 0.4 mg/kg + nalbuphine ED95) :Group A was given nalbuphine ED95, followed by cyclopofol 0.4mg/kg, and a laryngeal mask was placed when the patient s eyelash reflex disappeared and the Na
B (cyclopofol 0.4 mg/kg + sufentanil 0.1 µg/kg) 2:Group B was given sufentanil 0.1 µg/kg, then cyclopofol 0.4 mg/kg, and when the patient s eyelash reflex disappeared, the laryngeal mask was placed wh
Sponsors
The First People's Hospital of Jingzhou City
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Age 18~60 years old, ASA classification I.~II., BMI 18.0~28.0kg/m2, Mallampati grade I or II, mouth opening > 2.5cm, no airway abnormality, no long-term use of sedative-hypnotic drugs, history of alcohol dependence.
Exclusion criteria
Exclusion criteria: Those who refuse to participate or are not suitable to participate in this trial; Those who are clearly allergic to cyclopofol or nalbuphine; Patients with severe cardiovascular disease, severe diabetes mellitus, hyperkalemia, liver and kidney dysfunction or impaired adrenal cortical function; Patients with central nervous system disease, difficult airway, and acute upper respiratory tract infection; Previous use of sedative-hypnotic drugs, history of drug or alcohol dependence; History of alcohol abuse or taking psychotropic drugs or analgesic drugs within 24 hours before surgery; Patients with severe visual or hearing impairment or who are unable to communicate with the visitor or refuse to communicate for other reasons; history of psychological problems or psychiatric illness; Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Laryngeal mask placement reaction; | — |
Secondary
| Measure | Time frame |
|---|---|
| The HR, SBP, DBP, MAP, and Narcotrend indices were used at six time points before administration (T0), 1 min after administration (T1), 1 minute after laryngeal mask insertion, 5 min (T3), hysteroscopy into the uterine cavity (T4), and at the end of surgery (T5).; | — |
Countries
China
Contacts
Public ContactYi Chen
The First People's Hospital of Jingzhou City
Outcome results
None listed